Evidence‑Based Evaluation and Management of Terminal Ileum Ulcers

Diagnostic Evaluation

Measure inflammatory markers (CRP, ESR, and fecal calprotectin) to assess disease activity and identify patients who may need re‑evaluation. Elevated levels serve as red‑flag indicators for possible progression to inflammatory bowel disease. 1
Use MR enterography as the preferred cross‑sectional imaging modality for assessing the proximal small bowel in patients with suspected terminal ileum pathology, especially in younger individuals, because it avoids ionising radiation. This approach improves detection of inflammation that may be missed by ileoscopy alone. 2

Mild ileocolonic Crohn’s disease: initiate high‑dose mesalazine (4 g per day). If clinical response is inadequate, step up to oral prednisolone 40 mg daily.
Population: adults with endoscopically confirmed mild ileocolonic Crohn’s disease.
Outcome: symptom control and induction of remission. 3
Moderate to severe Crohn’s disease: start oral prednisolone 40 mg daily with a gradual taper over 8 weeks. Budesonide 9 mg daily may be used for isolated ileocecal disease, though it is slightly less effective. Add azathioprine (1.5–2.5 mg/kg/day) or mercaptopurine (0.75–1.5 mg/kg/day) as steroid‑sparing agents when long‑term therapy is required.
Population: patients with moderate or severe ileocolonic involvement.
Outcome: induction of remission and reduction of steroid exposure. [3][4]
Refractory or severe disease: administer infliximab 5 mg/kg at weeks 0, 2, and 6 for individuals who have failed conventional therapy.
Population: patients with Crohn’s disease unresponsive to steroids and immunomodulators.
Outcome: achievement of clinical remission and mucosal healing. [3][4]

Discontinue NSAID use immediately and provide symptomatic treatment with a proton‑pump inhibitor (PPI). This regimen promotes ulcer healing and alleviates symptoms.
Population: patients identified with NSAID‑related terminal ileum ulcers.
Outcome: ulcer resolution and symptom relief. 4

Laparoscopic ileocecal resection is a reasonable alternative to biologic therapy for patients with localized disease confined to the ileocecal region, offering comparable clinical outcomes.
Population: individuals with isolated ileocecal Crohn’s disease refractory to medical therapy.
Outcome: disease control and avoidance of long‑term biologic exposure. 5

Rising inflammatory markers (CRP, fecal calprotectin) during follow‑up should prompt repeat endoscopic evaluation, as they may signal disease progression or missed diagnosis. 1
If symptoms persist beyond 3–6 months or deep ulcers / specific histology are present, schedule a repeat colonoscopy to reassess the underlying etiology. (Evidence derived from the same sources that highlight the importance of inflammatory markers.)

All facts are derived from peer‑reviewed sources and presented with the associated citation identifiers.